Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Breast 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Sarcoma 9Rhabdomyosarcoma 9Sarcoma, Ewing 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma, Alveolar 2Pancreatic Neoplasms 2Neuroblastoma 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Connective and Soft Tissue 1Medulloblastoma 1Malignant mesenchymal tumor 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Fibrosarcoma 1

Interventions

Gemcitabine 5Docetaxel 4tislelizumab 3Bortezomib 3spartalizumab 2pembrolizumab 2Nivolumab 2Irinotecan 2Filgrastim 2Cisplatin 2Capecitabine 2130-nm albumin-bound paclitaxel 2trastuzumab deruxtecan 1tinostamustine 1talazoparib 1surufatinib 1regorafenib 1pazopanib 1pamiparib 1liposomal doxorubicin 1isophosphamide mustard 1futibatinib 1etoposide phosphate 1entinostat 1cc-486 1cabozantinib 1atezolizumab 1anlotinib 1Vinorelbine 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Vinorelbine × Sarcoma × Clear all
NCT02331251 2018-07-02

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Western Regional Medical Center

Phase 1/2 Terminated
81 enrolled
BreastGastrointestinalSarcomaThoracic

Breast Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡